Genomas Awarded $1.4 Million NIH SBIR Grant to Develop MRI+DNA Guided Biomarker System...

Genomas Awarded $1.4 Million NIH SBIR Grant to Develop MRI+DNA Guided
Biomarker System for Mental Illness
Pioneering Product Integrates Brain Imaging and Physiogenomics for Clinical
Neuroscience and Personalized Psychiatry

HARTFORD, Conn., Sept. 15 /PRNewswire/ -- Genomas(R), a biomedical company
advancing DNA-Guided medicine, today announced the award of a 3-year Phase II
Small Business Innovation Research (SBIR) Grant totaling $1.4 Million. The
grant, entitled MRI DNA Biomarkers for Neuropsychiatric Disease, was awarded
by the National Institute of Mental Health.

In announcing the award, Gualberto Ruano, M.D., Ph.D., President/CEO of
Genomas and Director of Genetics Research at Hartford Hospital commented: "The
interface of fMRI and physiogenomics provides a powerful platform for DNA
Guided Medicine in mental health. We believe this program will add new
efficacy and drug selection components to our existing and future DNA-guided
PhyzioType(TM) systems for personalized prescription of antidepressants and
antipsychotics. It will open significant new venues for interdisciplinary
translational research and commercial strategic partnering in clinical
neuroscience."

This Phase II program integrates the Genomas physiogenomics technology with
the leading fMRI research of Godfrey Pearlson M.D., at Hartford Hospital's
Institute of Living, and the advanced neuro-informatics capabilities of
Vincent Calhoun Ph.D., at the Mind Research Network and the University of New
Mexico. MIND Institute, University of New Mexico. The research leading to this
award has been published by this collaborative group in the renowned journals
Human Brain Mapping and Annals of Biomedical Engineering.

To date, Genomas has secured $4.8 Million of NIH SBIR funding for
PhyzioType(TM) product development. PhyzioType(TM) Systems are composed of an
ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by
a bioclinical algorithm in order to convey to physicians predicted comparisons
of efficacy and side effect risk among drugs for the individual patient. They
are currently available for DNA-Guided Medicine in the prescription of
antidepressants and in advanced development for antipsychotic, lipid-lowering,
and hypoglycemic drugs. The company's clinical phrarmacogenetic tests and
consultation service are provided through its Laboratory of Personalized
Health (LPH), an accredited and licensed high-complexity molecular diagnostic
center. Genomas is located on the campus of Hartford Hospital. For more
information, access www.genomas.net.

SOURCE Genomas

Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas, Inc.,
+1-860-545-4574